Remember8 Aug 2019 18:48
The Group has significant liquid resources in the form of cash reserves of €1.8 million and equity investments which can be readily liquidated for €14.1 million at the year end (Feb 19).
I haven’t seen anywhere starting we have touched the €14.1 mil and poly price has risen.
As of today our mcap is £15mil (Euro v pound about the same).
This makes the company totally unvalued on the bio med product, and the associated IP
If we take someone like Motif Bio, with a drug that failed FDA, they have a mcap of £8mil priced on a failed submission to FDA so they don’t even know it works! Our drug WORKS.
So let’s add a conservative £8mil to the mcap (although given how the drug has performed I believe it should be ALOT more than this), it would equate to a mcap of £23mil or share price 25p MINIMUM
Now, that’s on a worst case using Motif Bio and a failed drug years from market if ever at market.
You then look at Faron, however they have two drugs one of which is cancer and both show superb signs but it’s also a different bio market commercially. Their mcap is £40mil, but we would probably have to discount that crudely for the reasons above, by around 60%, so that gives a mcap of circa £24mill
So, on simple comparison to our piers, you could say we should be between £23mil and £40mill mcap
Or 25p - 45p at this stage
So yes whilst some may be burnt on the scum of twitter, this is still a very undervalued share and it will take one good RNS and we are well into the mid 20s.
Now the sellers are cleared, a good RNS or confirmation of filing for Russia (in the next 4-6 weeks), with only 47.5% free float, take away those not selling, I am convinced this has serious legs over the next month
Today was just a big dump, let them out, focus on facts
Good luck